Literature DB >> 29330152

Risk of Infection in Type 1 and Type 2 Diabetes Compared With the General Population: A Matched Cohort Study.

Iain M Carey1, Julia A Critchley2, Stephen DeWilde2, Tess Harris2, Fay J Hosking2, Derek G Cook2.   

Abstract

OBJECTIVE: We describe in detail the burden of infections in adults with diabetes within a large national population cohort. We also compare infection rates between patients with type 1 and type 2 diabetes mellitus (T1DM and T2DM). RESEARCH DESIGN AND METHODS: A retrospective cohort study compared 102,493 English primary care patients aged 40-89 years with a diabetes diagnosis by 2008 (n = 5,863 T1DM and n = 96,630 T2DM) with 203,518 age-sex-practice-matched control subjects without diabetes. Infection rates during 2008-2015, compiled from primary care and linked hospital and mortality records, were compared across 19 individual infection categories. These were further summarized as any requiring a prescription or hospitalization or as cause of death. Poisson regression was used to estimate incidence rate ratios (IRRs) between 1) people with diabetes and control subjects and 2) T1DM and T2DM adjusted for age, sex, smoking, BMI, and deprivation.
RESULTS: Compared with control subjects without diabetes, patients with diabetes had higher rates for all infections, with the highest IRRs seen for bone and joint infections, sepsis, and cellulitis. IRRs for infection-related hospitalizations were 3.71 (95% CI 3.27-4.21) for T1DM and 1.88 (95% CI 1.83-1.92) for T2DM. A direct comparison of types confirmed higher adjusted risks for T1DM versus T2DM (death from infection IRR 2.19 [95% CI 1.75-2.74]). We estimate that 6% of infection-related hospitalizations and 12% of infection-related deaths were attributable to diabetes.
CONCLUSIONS: People with diabetes, particularly T1DM, are at increased risk of serious infection, representing an important population burden. Strategies that reduce the risk of developing severe infections and poor treatment outcomes are under-researched and should be explored.
© 2018 by the American Diabetes Association.

Entities:  

Mesh:

Year:  2018        PMID: 29330152     DOI: 10.2337/dc17-2131

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  132 in total

Review 1.  Human Melioidosis.

Authors:  I Gassiep; M Armstrong; R Norton
Journal:  Clin Microbiol Rev       Date:  2020-03-11       Impact factor: 26.132

Review 2.  Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literature.

Authors:  Prasad Katulanda; Harsha A Dissanayake; Ishara Ranathunga; Vithiya Ratnasamy; Piyumi S A Wijewickrama; Nilukshana Yogendranathan; Kavinga K K Gamage; Nipun L de Silva; Manilka Sumanatilleke; Noel P Somasundaram; David R Matthews
Journal:  Diabetologia       Date:  2020-05-14       Impact factor: 10.122

3.  A risk score for predicting hospitalization for community-acquired pneumonia in ITP using nationally representative data.

Authors:  Ye-Jun Wu; Ming Hou; Hui-Xin Liu; Jun Peng; Liang-Ming Ma; Lin-Hua Yang; Ru Feng; Hui Liu; Yi Liu; Jia Feng; Hong-Yu Zhang; Ze-Ping Zhou; Wen-Sheng Wang; Xu-Liang Shen; Peng Zhao; Hai-Xia Fu; Qiao-Zhu Zeng; Xing-Lin Wang; Qiu-Sha Huang; Yun He; Qian Jiang; Hao Jiang; Jin Lu; Xiang-Yu Zhao; Xiao-Su Zhao; Ying-Jun Chang; Lan-Ping Xu; Yue-Ying Li; Qian-Fei Wang; Xiao-Hui Zhang
Journal:  Blood Adv       Date:  2020-11-24

4.  T Lymphocyte Subsets Associated With Prevalent Diabetes in Veterans With and Without Human Immunodeficiency Virus.

Authors:  Samuel S Bailin; Kathleen A McGinnis; Wyatt J McDonnell; Kaku So-Armah; Melissa Wellons; Russell P Tracy; Margaret F Doyle; Simon Mallal; Amy C Justice; Matthew S Freiberg; Alan L Landay; Celestine Wanjalla; John R Koethe
Journal:  J Infect Dis       Date:  2020-06-29       Impact factor: 5.226

5.  Opposite effects of statins on the risk of tuberculosis and herpes zoster in patients with diabetes: A population-based cohort study.

Authors:  Sheng-Wei Pan; Yung-Feng Yen; Jia-Yih Feng; Pei-Hung Chuang; Vincent Yi-Fong Su; Yu Ru Kou; Wei-Juin Su; Yu-Jiun Chan
Journal:  Br J Clin Pharmacol       Date:  2020-01-28       Impact factor: 4.335

6.  Diabetes Exacerbates Sepsis-Induced Neuroinflammation and Brain Mitochondrial Dysfunction.

Authors:  Solange de Souza Stork; Marcos Hübner; Erica Biehl; Lucineia Gainski Danielski; Sandra Bonfante; Larissa Joaquim; Tais Denicol; Thaina Cidreira; Anita Pacheco; Erick Bagio; Everton Lanzzarin; Gabriela Bernades; Mariana Pacheco de Oliveira; Larissa Espindola da Silva; Josiel M Mack; Franciane Bobinski; Gislaine Tezza Rezin; Tatiana Barichello; Emilio Luiz Streck; Fabricia Petronilho
Journal:  Inflammation       Date:  2022-06-10       Impact factor: 4.092

Review 7.  The Impact of Obesity on Disease Activity and Treatment Response in Rheumatoid Arthritis.

Authors:  Dilli Poudel; Michael D George; Joshua F Baker
Journal:  Curr Rheumatol Rep       Date:  2020-08-01       Impact factor: 4.592

8.  Comorbid Diabetes in Inflammatory Bowel Disease Predicts Adverse Disease-Related Outcomes and Infectious Complications.

Authors:  Anand Kumar; Tatiana Teslova; Erin Taub; Joshua D Miller; Dana J Lukin
Journal:  Dig Dis Sci       Date:  2020-07-02       Impact factor: 3.199

Review 9.  Extrapulmonary manifestations of COVID-19.

Authors:  Aakriti Gupta; Mahesh V Madhavan; Kartik Sehgal; Nandini Nair; Shiwani Mahajan; Tejasav S Sehrawat; Behnood Bikdeli; Neha Ahluwalia; John C Ausiello; Elaine Y Wan; Daniel E Freedberg; Ajay J Kirtane; Sahil A Parikh; Mathew S Maurer; Anna S Nordvig; Domenico Accili; Joan M Bathon; Sumit Mohan; Kenneth A Bauer; Martin B Leon; Harlan M Krumholz; Nir Uriel; Mandeep R Mehra; Mitchell S V Elkind; Gregg W Stone; Allan Schwartz; David D Ho; John P Bilezikian; Donald W Landry
Journal:  Nat Med       Date:  2020-07-10       Impact factor: 53.440

Review 10.  Divergent Sepsis Pathophysiology in Older Adults.

Authors:  Meagan S Kingren; Marlene E Starr; Hiroshi Saito
Journal:  Antioxid Redox Signal       Date:  2021-10-01       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.